Skip to main
Skip to main
University-wide Navigation

Under the directorship of Professor Khaled Shaaban, CPRI has developed the CPRI Natural Products Repository as UK-exclusive enabling resource. This repository is a growing collection of >420 pure natural products (>50% of which are unique to our collection) produced by microbes isolated from subterranean environments in Appalachian Kentucky (through strategic collaborations with KY-based underground mining and drilling operations). This effort has expanded to include strategic international collaborations to enable access to new ecological niches and natural products (Dr. Chirlei Glienke, Federal University of Paraná;  Dr. Imran Sajid, University of the Punjab, Pakistan; Dr. Changsheng Zhang, South China Sea Institute of Oceanology, China). As part of our natural products emphasis, CPRI also houses >1100 distinct actinomycete strains and corresponding fractionated extracts in screenable format. CPRI has also identified overproduction sources for a number of specialty natural products and continues to build a collection of UK-exclusive synthetics to further facilitate translational research activities.

In addition to the UK-exclusive compound collections emphasized above, CPRI continues to maintain and build a collection of commercially-sourced compound collections to support screening projects (including those focused on drug repurposing/repositioning). All CPRI compound collections listed below are available in a standard screenable format via the Translational Core and, for select projects, compounds can also be provided on larger scale for medicinal chemistry, mechanistic studies, in vivo assessment /andor development activities through the Synthesis Core.

Commercial Compound Collections (standard screening stocks)

UK-Exclusive Compound Collections (standard screening stocks)

  • CPRI Natural Products Repository (>420 pure structurally-characterized microbial natural products, >50% exclusive to UK/CPRI)
  • CPRI Synthetics Repository (>800 pure synthetic or semi-synthetics, >75% exclusive to UK)

Specialty Natural Products (solid stocks, ≥10 mg quantities)

  • Actinomycin D (Dactinomycin, Chounghwamycin B, Cosmegen, Meractinomycin, NCI C04682)
  • AT2433-A1
  • AT2433-B1
  • Coumabiocin A
  • Elaiophylin (Azalomycin B, Salbomycin, Gopalamicin, SNA-4606-3)
  • Geldanamycin (NSC 122750, NSC 212518)
  • 19-Hydroxy-geldanamycin
  • Herbicidin A
  • Herbicidin B
  • Herbimycin A (NSC 305978, Antibiotic TAN 420F)
  • Mithramycin A (Plicamycin, Plicatomycin, Mithracin, NSC 24559, Aureolic acid)
  • Mithramycin SA
  • Mithramycin SK
  • Nocardamine (Deferrioxamine E, Deferriferrioxamine E, Desferrioxamine E, Proferrioxamine E)
  • Novobiocin (Albamycin, Cathomycin, Streptonivicin, Inamycin, Cardelmycin, Sirbiocina)
  • Oxachelin
  • Scopafungin (Nificin, Niphimycin I alpha, NSC 107041, U 29479)
  • Venturicidin A (Aabomycin A1, Venturicidin B-3'-carbamate)
  • Venturicidin B (Aabomycin A2)

Representative Publications

UK Looks for Natural Products in Kentucky's Unique Environments

Inquiries

The CPRI seeks to develop innovative research partnerships with UK investigators. For more information and to request services, please contact us.

Contact Us

Funding Acknowledgment Statement

This work was supported by the Center for Pharmaceutical Research and Innovation (CPRI, NIH P20 GM130456) and the National Center for Advancing Translational Sciences (UL1 TR001998).